Fig. 1 · Structure

Documents & Downloads

Dynemicin A

Cat. No. A13848 CAS 124412-57-3
Dynemicin A is an antitumor natural product isolated from Micromonospora chersina which causes DNA strand cleavage.

This product is currently unavailable.

Ask us for lead time and price.

Inquire about this product

Publications for Dynemicin A

1 publication citing this product

  1. Chowdhury N, .et al. , Biotechnol Bioeng, 2016, Sep;113(9):1984-92 PMID: 26914280

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Dynemicin A cleaved DNA in a NADPH-activated sequencing assay. DNA-binding-agent perturbations support a minor-groove interaction, while anthraquinone intercalation and radical-mediated cleavage were proposed as the mechanism. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

In Vitro Studies

Dynemicin A showed cytotoxicity across the tested tumor-cell panel, with IC50 values dependent on cell line and exposure duration. These assays do not establish selectivity over normal cells. [2]

Sequence-resolved DNA cleavage

Biochemical assay · End-labeled 128-bp Sal I–Dra II pBR322 DNA fragment [1]

Dynemicin produced sequence-dependent cleavage in the NADPH system.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
DNA strand scissionQualitative cleavage pattern Preferred sites were 3′ of purines, including 5′-AG, -GC and -AT; intact-DNA lanes were included.[1]

Literature-Reported Treatment Conditions

Treatment concentration
50 μM dynemicin; 5 mM NADPH
Exposure duration
5 h
Method
37°C; sequencing-gel analysis
Co-treatment
NADPH activation; not a drug-combination efficacy experiment.
Reported limits
Drug solvent and replication/uncertainty not specified for Fig. 2.
Methods and source locations

Compound reported in the paper: Dynemicin A; Compound label in the paper: Dynemicin

Evidence concerns the authors’ material, without validation of an Adooq lot or its enantiomeric purity.

pp. 3831–3832, assay/sequence methods and Fig. 2

DNA strand scission: Denaturing sequencing gel; both end-label orientations. — p. 3832, Fig. 2 and Sequence-Specific DNA Cleavage

DNA-binding perturbation of cleavage

Biochemical assay · End-labeled pBR322 DNA fragments pretreated with DNA-binding agents [1]

Blocker-dependent changes support a minor-groove interaction; intercalation and radical formation remain mechanistic interpretation.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Change in dynemicin cleavage after DNA pretreatmentQualitative inhibition/pattern change Distamycin A and anthramycin strongly inhibited cleavage; Adriamycin and actinomycin D altered or inhibited the pattern.[1]

Literature-Reported Treatment Conditions

Treatment concentration
DNA pretreatment: 50 μM agent; cleavage: 50 μM dynemicin and 5 mM NADPH
Exposure duration
Pretreatment 30 min; cleavage 5 h
Method
37°C; sequencing-gel analysis
Co-treatment
DNA-binding agent pretreatment, followed by dynemicin/NADPH.
Reported limits
No affinity constant or statistical uncertainty is reported for this adopted qualitative comparison.
Methods and source locations

Compound reported in the paper: Dynemicin A; Compound label in the paper: Dynemicin

Evidence concerns the authors’ material, without validation of an Adooq lot or its enantiomeric purity.

pp. 3831–3834, nucleotide sequence methods, Fig. 4, results and discussion

Change in dynemicin cleavage after DNA pretreatment: Sequencing gels compared with dynemicin alone and intact DNA. — pp. 3832–3833, Fig. 4 and Alteration of Dynemicin-Induced DNA Cleavage

Tumor-cell cytotoxicity panel

Cell-based study · Murine melanoma/leukemia and human colon carcinoma/leukemia cell lines [2]

Sensitivity varied by cell line; the tested resistant sublines retained sensitivity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
B16-F10 viable-cell endpointIC50 4.1 ng/ml[2]
P388 viable-cell endpointIC50 0.021 ng/ml[2]
P388/VCR viable-cell endpointIC50 0.019 ng/ml[2]
P388/ADM viable-cell endpointIC50 0.022 ng/ml[2]
HCT-116 viable-cell endpointIC50 0.28 ng/ml[2]
Moser viable-cell endpointIC50 0.0027 ng/ml[2]
K562 viable-cell endpointIC50 0.024 ng/ml[2]
K562/ADM viable-cell endpointIC50 0.026 ng/ml[2]

Literature-Reported Treatment Conditions

Exposure duration
72 h except K562/K562/ADM: 48 h
Method
Neutral red at 540 nm or viable-cell counting, depending on line.
Vehicle
DMSO followed by dilution with sterile 0.9% NaCl or water; final DMSO fraction unspecified.
Reported limits
Concentration series, replicate counts, uncertainty and explicit cell-assay vehicle-control layout are not specified in the acquired text.
Methods and source locations

Compound reported in the paper: Dynemicin A; Compound label in the paper: Dynemicin A

Evidence concerns the authors’ material, without validation of an Adooq lot or its enantiomeric purity.

pp. 1306–1308, Drug Preparation, In Vitro Cytotoxicity, Table 1

B16-F10 viable-cell endpoint: 72 h; neutral-red viable-cell assay — p. 1308, Table 1; p. 1307, In Vitro Cytotoxicity

P388 viable-cell endpoint: 72 h; viable-cell counting — p. 1308, Table 1; p. 1307, In Vitro Cytotoxicity

P388/VCR viable-cell endpoint: 72 h; viable-cell counting — p. 1308, Table 1; p. 1307, In Vitro Cytotoxicity

P388/ADM viable-cell endpoint: 72 h; viable-cell counting — p. 1308, Table 1; p. 1307, In Vitro Cytotoxicity

HCT-116 viable-cell endpoint: 72 h; neutral-red viable-cell assay — p. 1308, Table 1; p. 1307, In Vitro Cytotoxicity

Moser viable-cell endpoint: 72 h; neutral-red viable-cell assay — p. 1308, Table 1; p. 1307, In Vitro Cytotoxicity

K562 viable-cell endpoint: 48 h; viable-cell counting — p. 1308, Table 1; p. 1307, In Vitro Cytotoxicity

K562/ADM viable-cell endpoint: 48 h; viable-cell counting — p. 1308, Table 1; p. 1307, In Vitro Cytotoxicity

In Vivo Studies

In the intravenous P388 leukemia mouse model, dynemicin A prolonged median survival at selected doses; higher doses also produced weight loss. A separate single-dose study found delayed toxicity in non-tumor-bearing mice. [2]

Survival in the intravenous P388 leukemia model

Animal study · Mice bearing intravenously implanted P388 leukemia; female CDF1 and male BDF1 mice are listed in shared methods without explicit model assignment. [2]

Survival increased at selected doses, with weight loss at higher doses.

Conditions shared by the study groups

Route
Intravenous
Frequency
Once daily on days 1–3 (Q1D × 3)
Treatment course
Three administrations; survival observation through day 45.
Vehicle
DMSO diluted with sterile 0.9% NaCl or water; final composition unspecified.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Dynemicin A dose series
1.0, 0.5, 0.25, 0.13 mg/kg/day
Vehicle-treated mice: MST 9.0 days; day-4 average weight change +0.8 g.In dose order: MST 16.0, 14.0, 12.0, 10.0 days; T/C 178%, 156%, 133%, 111%; day-4 weight change −1.3, −0.8, 0.0, +0.3 g.[2]
Doxorubicin comparator series
8.0, 4.0, 2.0, 1.0 mg/kg/day
Vehicle-treated mice: MST 9.0 days; day-4 average weight change +0.8 g.In dose order: MST 16.0, 14.0, 10.5, 9.5 days; T/C 178%, 156%, 117%, 106%; day-4 weight change −2.3, −0.5, +0.3, +0.5 g.[2]
Dynemicin A dose series
Model: Mice bearing intravenously implanted P388 leukemia
Reported limits: Efficacy group size, randomization, blinding, uncertainty and model-specific strain assignment are not explicit.
Doxorubicin comparator series
Model: Mice bearing intravenously implanted P388 leukemia
Reported limits: Efficacy group size, randomization, blinding, uncertainty and model-specific strain assignment are not explicit.
Methods and source locations

Compound reported in the paper: Dynemicin A; Compound label in the paper: Dynemicin A

Evidence concerns the authors’ material, without validation of an Adooq lot or its enantiomeric purity.

pp. 1306–1307, shared animal methods; p. 1309, Table 5 (P388 iv)

Dynemicin A dose series · p. 1309, Table 5, P388 leukemia (iv); pp. 1306–1307, shared methods

Doxorubicin comparator series · p. 1309, Table 5, P388 leukemia (iv); pp. 1306–1307, shared methods

Separate single-dose mouse toxicity assessment

Animal study · Non-tumor-bearing male ddY mice, 20–24 g; groups of 5–8 mice [2]

Delayed lethality limits interpretation of antitumor activity.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Ten-day lethality after a single intraperitoneal doseLD50 0.58 mg/kg ip[2]
Onset of deaths at the highest tested doseFirst observed death 3 days after 10 mg/kg ip[2]

Conditions shared by the study groups

Route
Intraperitoneal
Frequency
Single administration
Treatment course
Single exposure; LD50 calculated on day 10.
Vehicle
Shared Drug Preparation: DMSO diluted with sterile 0.9% NaCl or water.
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Dynemicin A single-dose toxicity series
Graded doses; 10 mg/kg was the highest tested dose. The complete administered dose series is not reported.
No separate control group is described for this toxicity experiment.Day-10 LD50 was 0.58 mg/kg ip; first death at the highest tested dose (10 mg/kg) occurred 3 days after administration.[2]
Dynemicin A single-dose toxicity series
Model: Non-tumor-bearing male ddY mice, 20–24 g; groups of 5–8 mice
Reported limits: Complete dose-group mortality data, all administered dose levels, a separate control group, final vehicle composition, uncertainty, randomization and blinding are not reported.
Methods and source locations

Compound reported in the paper: Dynemicin A; Compound label in the paper: Dynemicin A

Evidence concerns the authors’ material, without validation of an Adooq lot or its enantiomeric purity.

p. 1307 and pp. 1309–1310, Acute Toxicity in Mice

Ten-day lethality after a single intraperitoneal dose: Van der Waerden calculation on day 10. — p. 1307, Acute Toxicity in Mice; pp. 1309–1310, Acute Toxicity results

Onset of deaths at the highest tested dose: Single-dose assessment; not the efficacy schedule. — p. 1310, Acute Toxicity results

Dynemicin A single-dose toxicity series · p. 1306, Drug Preparation; p. 1307, Acute Toxicity in Mice; p. 1310, Acute Toxicity results

Specifications

Manufacturer Adooq Bioscience
CAS Number 124412-57-3
Formula C30H19NO9
Molecular Weight 537.478
Synonyms Dynemicin
SMILES
C[C@H]1C(=C([C@H]2C#C/C=C\C#C[C@H]3[C@]14[C@]2(O4)C5=CC(=C6C(=C5N3)C(=O)C7=C(C=CC(=C7C6=O)O)O)O)OC)C(=O)O

Storage & Solubility

In Vitro Solubility

Reported Solubility

No reported solubility data are available for this product.

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Research References

  1. [1] Yukio Sugiura, Takashi Shiraki, Masataka Konishi, et al. DNA intercalation and cleavage of an antitumor antibiotic dynemicin that contains anthracycline and enediyne cores. Proceedings of the National Academy of Sciences of the United States of America (1990). PMID: 2339123 DOI: 10.1073/pnas.87.10.3831 Source material
  2. [2] Hideo Kamei, Yuji Nishiyama, Akiyo Takahashi, et al. Dynemicins, new antibiotics with the 1,5-diyn-3-ene and anthraquinone subunit. II. Antitumor activity of dynemicin A and its triacetyl derivative. The Journal of Antibiotics (1991). PMID: 1778783 DOI: 10.7164/antibiotics.44.1306 Source material

Publications

1 publication citing this product

  1. Chowdhury N, .et al. , Biotechnol Bioeng, 2016, Sep;113(9):1984-92 PMID: 26914280

Added to your cart

View Cart Checkout
Loading...